Glaxo Profit Misses Estimates as Price Hurts Europe Sales

GlaxoSmithKline Plc, the U.K.’s largest drugmaker, reported third-quarter profit and sales that fell more than analysts estimated as revenue declined in Europe and a vaccine program in Japan came to an end.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.